Last reviewed · How we verify
Vinflunine plus Capecitabine
Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase.
Vinflunine is a chemotherapeutic agent that intercalates DNA, thereby inhibiting DNA replication and transcription, while Capecitabine is a prodrug that is converted into 5-fluorouracil, which inhibits thymidylate synthase. Used for Advanced or metastatic transitional cell carcinoma of the urothelial tract.
At a glance
| Generic name | Vinflunine plus Capecitabine |
|---|---|
| Also known as | JAVLOR, L00070 IN |
| Sponsor | Pierre Fabre Medicament |
| Drug class | Platinum-based chemotherapeutic agent and fluoropyrimidine |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Vinflunine's mechanism of action involves intercalating DNA, which prevents the replication and transcription of DNA. This leads to cell death, particularly in rapidly dividing cancer cells. Capecitabine, on the other hand, is converted into 5-fluorouracil, which inhibits thymidylate synthase, an enzyme necessary for DNA synthesis. This inhibition of DNA synthesis also leads to cell death.
Approved indications
- Advanced or metastatic transitional cell carcinoma of the urothelial tract
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Diarrhea
- Nausea
- Vomiting
- Fatigue
- Mucositis
Key clinical trials
- Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer (PHASE3)
- Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer (PHASE3)
- Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinflunine plus Capecitabine CI brief — competitive landscape report
- Vinflunine plus Capecitabine updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI